search
Back to results

INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)

Primary Purpose

HIV/AIDS

Status
Active
Phase
Not Applicable
Locations
Uganda
Study Type
Interventional
Intervention
Daily Text Messages
Incentivization based on timely ART adherence
Sponsored by
RAND
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV/AIDS focused on measuring ART Adherence, Reminders, Behavioral Economics, Viral Suppression, Long-term Adherence, Routines, Habit Formation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female clients age 18 and older.
  • Started ART at Mildmay or another clinic within the preceding three months but have since been receiving care at Mildmay.
  • Able to speak and understand either English or Luganda.
  • Have their own cell phone or have consistent access to someone else's phone.
  • Willing to receive daily text messages for the 3 months of intervention duration.
  • Willing and able to use the MEMS caps distributed for adherence verification for the duration of the study.

Exclusion Criteria:

  • Not mentally fit to consent.
  • Language other than Luganda or English.
  • Not willing to consistently use the MEMS caps device for adherence measurement.

Sites / Locations

  • Mildmay Uganda Limited

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Experimental

Experimental

Arm Label

Control

Intervention group receiving messages (Messages Group)

Intervention group receiving messages and incentives (Incentives Group)

Arm Description

This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices. At recruitment participant will be explained the importance of pill-taking. All participants (including in the control group) will receive a leaflet containing detailed information on how to establish healthy pill-taking routines. Finally, clinic staff will counsel participants on how to select an already regularly routine behavior that occurs at roughly the same time each day that forms the basis of their implementation plan.

Participants will receive the same information as those in the Control Group, but in addition, receive the "Daily Text Message" Intervention.

Participants will receive the same information as the Control group. Additionally, they will receive the "Daily Text Message Intervention" and will be eligible for prize drawings.

Outcomes

Primary Outcome Measures

Electronically measured mean medication adherence during intervention
MEMS-data will be collected continuously over the course of the three-month intervention period allowing us to investigate mean adherence. Only one of the ART medications will be used to calculate the primary adherence variable (# of actual bottle openings / # of prescribed bottle openings).
Electronically measured mean medication adherence post intervention
MEMS-data will be collected continuously over the course of the six-month post intervention period allowing for the investigation of post-intervention mean adherence. Only one of the ART medications will be used to calculate the primary adherence variable (# of actual bottle openings / # of prescribed bottle openings).
Routinization of ART adherence during intervention
A novel measure of routine adherence (that it is explicitly based on the temporal pattern of pill-taking) will be used. It is calculated as the fraction of scheduled pills taken within a one-hour window around the typical time that participants report completing their existing routine behavior that anchors their pill-taking. This measure provides an objective way for determining behavioral automaticity of pill-taking.
Routinization of ART adherence post-intervention
This measure would be calculated as a fraction of scheduled pills taken within a one-hour window around the typical time that participants report completing their existing routine behavior that anchors their pill-taking, for all visits made post-intervention.

Secondary Outcome Measures

Retention in care
Retention in care will be measured as the fraction of participants recruited who are still active clients at the clinic at month 9.
Viral Suppression
HIV RNA (viral load) is the secondary outcome measure, and the investigators will also examine intervention effects on mean change in log-transformed viral load. Viral loads are now part of routine clinical care in Uganda and will be chart abstracted.

Full Information

First Posted
November 12, 2021
Last Updated
July 14, 2023
Sponsor
RAND
Collaborators
National Institute of Mental Health (NIMH), Mildmay Uganda Limited, Arizona State University
search

1. Study Identification

Unique Protocol Identification Number
NCT05131165
Brief Title
INcentives and ReMINDers to Improve Long-term Medication Adherence
Acronym
INMIND
Official Title
INcentives and ReMINDers to Improve Long-term Medication Adherence
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 25, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
August 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RAND
Collaborators
National Institute of Mental Health (NIMH), Mildmay Uganda Limited, Arizona State University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study will test the feasibility and acceptability of using text messages and behavioral economics-based incentives to support anchoring Anti-Retroviral Therapy (ART) adherence to an existing routine in order to improve long-term ART medication adherence. The intervention phase of the three-phased study will constitute the pilot RCT. A sample of 150 clients who have initiated ART in the preceding three months will be randomized to either usual care (C = 50) or one of the two INMIND intervention groups (daily text message reminders with or without incentives) for three months (T1 = 50; T2=50). Subsequently, behavioral persistence will be evaluated for six months post-intervention. Assessments will be conducted at baseline, month 3, and month 9. The primary outcomes are 1) electronically measured mean medication adherence during the intervention and 2) six months post intervention, along with 3) timeliness of medication adherence during the intervention and 4) six months post-intervention.
Detailed Description
Adherence of Anti-Retroviral Therapy (ART) among HIV-infected patients initiating treatment (treatment initiators) in Sub-Saharan Africa has remained low, even though the number of treatment initiators has increased in recent years. Lack of retention in care and low adherence in the first year of ART treatment are substantial barriers to virologic suppression. The current R34 study tests a novel approach for improving long-term ART adherence among treatment initiators by turning adherence into a behavioral routine. This is done in two ways: 1) anchoring ART adherence to an existing routine, and 2) providing more immediate rewards and increasing the salience through reminder messages. Insights from behavioral economics suggest that such an intervention may be particularly effective for people with present bias (those who have a tendency to give in to short-term temptation at the cost of more long-term benefits) and lack of salience (where over time, the choice of target behavior is overshadowed by more pressing needs of daily life) which have been found to be prevalent among people living with chronic medical conditions from past studies. The intervention will be tested through a pilot RCT, wherein 150 adult clients will be randomly assigned to three groups. The first intervention group would receive daily text messages that reinforce routine formation information provided to all participants (across the three groups). The second intervention group will receive the text messages, and additionally be eligible for a prize drawing based on timely ART adherence, at each monthly clinic visit. The control group will receive care as usual, consisting of routine formation information as well as adherence counseling. The intervention will last three months, with a six-month post-intervention follow up period. All participants will receive MEMS caps to record adherence, and will complete assessments over nine months (baseline, post-intervention, and six months post-intervention). The Specific Aim of the intervention phase of the study is to test the preliminary effectiveness of the intervention, including the relative effectiveness of the two different implementation approaches. This is preceded by the formative phase, with the Specific Aim of developing the intervention parameters. The intervention phase is succeeded by the adaptation phase, whose Specific Aim is to collect data in preparation for a subsequent R01 application.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV/AIDS
Keywords
ART Adherence, Reminders, Behavioral Economics, Viral Suppression, Long-term Adherence, Routines, Habit Formation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A pilot randomized controlled trial with two intervention arms and a control group, that will receive intervention for three months with follow-on assessment for six months after the intervention period ends.
Masking
InvestigatorOutcomes Assessor
Masking Description
The investigator and outcomes assessor will be blinded to treatment assignment of study participants.
Allocation
Randomized
Enrollment
166 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices. At recruitment participant will be explained the importance of pill-taking. All participants (including in the control group) will receive a leaflet containing detailed information on how to establish healthy pill-taking routines. Finally, clinic staff will counsel participants on how to select an already regularly routine behavior that occurs at roughly the same time each day that forms the basis of their implementation plan.
Arm Title
Intervention group receiving messages (Messages Group)
Arm Type
Experimental
Arm Description
Participants will receive the same information as those in the Control Group, but in addition, receive the "Daily Text Message" Intervention.
Arm Title
Intervention group receiving messages and incentives (Incentives Group)
Arm Type
Experimental
Arm Description
Participants will receive the same information as the Control group. Additionally, they will receive the "Daily Text Message Intervention" and will be eligible for prize drawings.
Intervention Type
Behavioral
Intervention Name(s)
Daily Text Messages
Intervention Description
Participants will receive daily text message reminders to use their routine behavior to trigger medication adherence.
Intervention Type
Behavioral
Intervention Name(s)
Incentivization based on timely ART adherence
Intervention Description
Participants will be eligible to draw a prize if they take their medication within +/- one hour of the stated existing routine to which pill-taking is anchored on at least 70% of days between recruitment and the 3-month study visit.
Primary Outcome Measure Information:
Title
Electronically measured mean medication adherence during intervention
Description
MEMS-data will be collected continuously over the course of the three-month intervention period allowing us to investigate mean adherence. Only one of the ART medications will be used to calculate the primary adherence variable (# of actual bottle openings / # of prescribed bottle openings).
Time Frame
Three months
Title
Electronically measured mean medication adherence post intervention
Description
MEMS-data will be collected continuously over the course of the six-month post intervention period allowing for the investigation of post-intervention mean adherence. Only one of the ART medications will be used to calculate the primary adherence variable (# of actual bottle openings / # of prescribed bottle openings).
Time Frame
Six months post-intervention
Title
Routinization of ART adherence during intervention
Description
A novel measure of routine adherence (that it is explicitly based on the temporal pattern of pill-taking) will be used. It is calculated as the fraction of scheduled pills taken within a one-hour window around the typical time that participants report completing their existing routine behavior that anchors their pill-taking. This measure provides an objective way for determining behavioral automaticity of pill-taking.
Time Frame
Three months
Title
Routinization of ART adherence post-intervention
Description
This measure would be calculated as a fraction of scheduled pills taken within a one-hour window around the typical time that participants report completing their existing routine behavior that anchors their pill-taking, for all visits made post-intervention.
Time Frame
Six months post-intervention
Secondary Outcome Measure Information:
Title
Retention in care
Description
Retention in care will be measured as the fraction of participants recruited who are still active clients at the clinic at month 9.
Time Frame
Month 9
Title
Viral Suppression
Description
HIV RNA (viral load) is the secondary outcome measure, and the investigators will also examine intervention effects on mean change in log-transformed viral load. Viral loads are now part of routine clinical care in Uganda and will be chart abstracted.
Time Frame
Month 9

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female clients age 18 and older. Started ART at Mildmay or another clinic within the preceding three months but have since been receiving care at Mildmay. Able to speak and understand either English or Luganda. Have their own cell phone or have consistent access to someone else's phone. Willing to receive daily text messages for the 3 months of intervention duration. Willing and able to use the MEMS caps distributed for adherence verification for the duration of the study. Exclusion Criteria: Not mentally fit to consent. Language other than Luganda or English. Not willing to consistently use the MEMS caps device for adherence measurement.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sebastian Linnemayr, Ph.D.
Organizational Affiliation
RAND
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mildmay Uganda Limited
City
Kampala
Country
Uganda

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data collected in the execution of the aims described in the application will be shared in the form of journal publications. Following publication of the main paper(s) for this study and the grant end-date, the RAND Human Subjects Protection Committee will be consulted about how to securely make data publicly available in the form of an electronic database for researchers who successfully complete a registration process (described below). Any shared data will be de-identified and will not contain any direct identifiers or indirect identifiers (that could identify participants by inference). No qualitative data will be shared, as such data would be difficult to de-identify given that participants will be telling their own experiences and thus could be identified by inference. Documentation of shared data will be provided in the form of a codebook in which each variable name and response options are defined.
IPD Sharing Time Frame
Will be decided after consultation with the RAND Human Subjects Protection Committee.
IPD Sharing Access Criteria
Access will be allowed post-registration, wherein accessing individuals will need to completed a data sharing agreement that outlines the conditions of use governing access to the public release data, including restrictions against attempting to identify study participants, destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistribution of the data to third parties, and proper acknowledgement of the data resource. The data sharing agreement will include a commitment to using the data only for research purposes, a commitment to securing the data using appropriate computer technology, and a commitment to destroying or returning the data after analyses are completed. Users must submit brief proposals regarding intended use of the data; the study team will determine the scientific soundness of the proposal as part of the decision for the researcher to be able to access the public use dataset.
Citations:
PubMed Identifier
19588667
Citation
Ruppar TM, Russell CL. Medication adherence in successful kidney transplant recipients. Prog Transplant. 2009 Jun;19(2):167-72. doi: 10.1177/152692480901900211.
Results Reference
background
PubMed Identifier
26148187
Citation
Phillips LA, Gardner B. Habitual exercise instigation (vs. execution) predicts healthy adults' exercise frequency. Health Psychol. 2016 Jan;35(1):69-77. doi: 10.1037/hea0000249. Epub 2015 Jul 6.
Results Reference
background
PubMed Identifier
21749245
Citation
Lally P, Wardle J, Gardner B. Experiences of habit formation: a qualitative study. Psychol Health Med. 2011 Aug;16(4):484-9. doi: 10.1080/13548506.2011.555774.
Results Reference
background
PubMed Identifier
33831632
Citation
Stecher C, Mukasa B, Linnemayr S. Uncovering a behavioral strategy for establishing new habits: Evidence from incentives for medication adherence in Uganda. J Health Econ. 2021 May;77:102443. doi: 10.1016/j.jhealeco.2021.102443. Epub 2021 Mar 16.
Results Reference
background
PubMed Identifier
33306553
Citation
Stecher C, Linnemayr S. Promoting antiretroviral therapy adherence habits: a synthesis of economic and psychological theories of habit formation. AIDS. 2021 Apr 1;35(5):711-716. doi: 10.1097/QAD.0000000000002792. No abstract available.
Results Reference
background
PubMed Identifier
32513192
Citation
Jennings Mayo-Wilson L, Devoto B, Coleman J, Mukasa B, Shelton A, MacCarthy S, Saya U, Chemusto H, Linnemayr S. Habit formation in support of antiretroviral medication adherence in clinic-enrolled HIV-infected adults: a qualitative assessment using free-listing and unstructured interviewing in Kampala, Uganda. AIDS Res Ther. 2020 Jun 8;17(1):30. doi: 10.1186/s12981-020-00283-2.
Results Reference
background
PubMed Identifier
25987190
Citation
Linnemayr S, Stecher C. Behavioral Economics Matters for HIV Research: The Impact of Behavioral Biases on Adherence to Antiretrovirals (ARVs). AIDS Behav. 2015 Nov;19(11):2069-75. doi: 10.1007/s10461-015-1076-0.
Results Reference
background
PubMed Identifier
28225450
Citation
Linnemayr S, Stecher C, Mukasa B. Behavioral economic incentives to improve adherence to antiretroviral medication. AIDS. 2017 Mar 13;31(5):719-726. doi: 10.1097/QAD.0000000000001387.
Results Reference
background
PubMed Identifier
29048966
Citation
Linnemayr S, Huang H, Luoto J, Kambugu A, Thirumurthy H, Haberer JE, Wagner G, Mukasa B. Text Messaging for Improving Antiretroviral Therapy Adherence: No Effects After 1 Year in a Randomized Controlled Trial Among Adolescents and Young Adults. Am J Public Health. 2017 Dec;107(12):1944-1950. doi: 10.2105/AJPH.2017.304089. Epub 2017 Oct 19.
Results Reference
background
PubMed Identifier
36315224
Citation
Stecher C, Ghai I, Lunkuse L, Wabukala P, Odiit M, Nakanwagi A, Linnemayr S. Incentives and Reminders to Improve Long-term Medication Adherence (INMIND): Protocol for a Pilot Randomized Controlled Trial. JMIR Res Protoc. 2022 Oct 31;11(10):e42216. doi: 10.2196/42216.
Results Reference
derived

Learn more about this trial

INcentives and ReMINDers to Improve Long-term Medication Adherence

We'll reach out to this number within 24 hrs